• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

    4/29/25 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNPR alert in real time by email

    WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025. EASL is recognized as one of the premier events in the hepatology space and will be held in Amsterdam, Netherlands from May 7 – 10, 2025.

    Late-breaker provides an opportunity to present "the most recent and significant findings," according to EASL. Criteria for late-breaker abstracts include: (1) they present the latest, up-to-date research findings; (2) the research is considered highly significant with the potential to impact the field in a substantial manner; and (3) clinical studies should be prospective. Late-breaker abstracts undergo a rigorous review, and the acceptance rate is lower than regular abstracts with only the most compelling abstracts selected.

    Details of the EASL Congress 2025 late-breaker poster presentation are as follows:

    Title: Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline

    Abstract Number: LB25251

    Session: Late-breaker Posters

    Date and Time: Wednesday, May 7, 8:30 a.m. CET

    Presenter: Karl Heinz Weiss, M.D.

    Location: Amsterdam, Netherlands

    The poster to be presented at EASL 2025 will be available online at www.monopartx.com on May 7, 2025.

    About Monopar Therapeutics Inc.

    Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com.

    CONTACT:

    Monopar Therapeutics Inc.

    Investor Relations

    Quan Vu

    Chief Financial Officer

    [email protected]

    Follow Monopar on social media for updates:

    X: @MonoparTx  LinkedIn: Monopar Therapeutics



    Primary Logo

    Get the next $MNPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNPR

    DatePrice TargetRatingAnalyst
    3/19/2025$76.00Overweight
    Piper Sandler
    1/10/2025$72.00Overweight
    Piper Sandler
    10/11/2024$50.00Buy
    Rodman & Renshaw
    11/1/2021$9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MNPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Radhakrishnan Karthik bought $25,188 worth of shares (1,550 units at $16.25) (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      10/30/24 4:17:28 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Cittadine Andrew bought $25,574 worth of shares (32,508 units at $0.79), increasing direct ownership by 21% to 186,132 units (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      6/21/24 5:16:51 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Cittadine Andrew bought $32,894 worth of shares (36,000 units at $0.91), increasing direct ownership by 31% to 153,624 units (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      6/17/24 6:08:20 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

      WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar," the "Company," "us" and "our") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, in collaboration with Excel Diagnostics and Nuclear Oncology Center ("EDNOC"), a premier diagnostic medical imaging and therapeutic nuclear medicine center, today announced that the physician-sponsored Expanded Access Program ("EAP") for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the U.S. Food and Drug Administration ("FD

      6/11/25 7:00:00 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

      WILMETTE, Ill., June 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the close of U.S. equity markets on June 27, 2025. The inclusion follows the initial announcement on Friday, May 23, and the subsequent update on Friday, May 30, 2025, in connection with the annual reconstitution of the Russell U.S. Indexes. The Russell 2000® Index tracks the performance of the small-c

      6/3/25 7:00:00 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

      WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025, a leading global conference in liver disease. The data support ALXN1840 as a potential treatment for Wilson disease

      5/13/25 8:00:00 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Monopar Therapeutics Inc.

      DEFA14A - Monopar Therapeutics (0001645469) (Filer)

      5/23/25 3:48:33 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.

      SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)

      5/14/25 11:59:32 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Monopar Therapeutics Inc.

      10-Q - Monopar Therapeutics (0001645469) (Filer)

      5/13/25 8:00:57 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tactic Pharma Llc sold $1,166,690 worth of shares (33,334 units at $35.00) (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      4/4/25 7:27:32 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Cittadine Andrew covered exercise/tax liability with 744 shares and converted options into 1,791 shares, increasing direct ownership by 3% to 41,985 units (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      4/2/25 9:08:37 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Robinson Chandler converted options into 4,106 shares and covered exercise/tax liability with 1,204 shares, increasing direct ownership by 5% to 65,993 units (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      4/2/25 9:07:37 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care